Earnings summary

Baxter International Inc Q2 2025 results

Reported 2025-07-31Full transcript →

Snapshot

Baxter International Inc reported $2.81B of revenue in Q2 2025, up 4.3% year over year, with diluted EPS of $0.24 and an operating margin of 6.8%.

Revenue
$2.81B
YoY growth
+4.3%
Diluted EPS
$0.24
Operating margin
6.8%
$2.81B
Revenue
+4.3%
YoY growth
$0.24
Diluted EPS
6.8%
Operating margin
01 Key takeaways

What management said

  • On the call this morning, we will be discussing Baxter's second quarter 2025 results along with our financial outlook for the third quarter and full year 2025.
  • As you saw in this morning's release, our second quarter performance for continuing operations met our previously issued guidance on both top and bottom line.
  • Specifically, second quarter sales from continuing operations grew 4% on a reported basis and 1% on an operational basis, with growth coming from all three segments.
  • On the bottom line, adjusted earnings per share from continuing operations were $0.59, increasing 28% over the prior year.
  • These results did come in at the low end of our guidance ranges, reflecting softness in demand for certain products within the Medical Products & Therapies and Pharmaceuticals segments.
  • We are confident in our strategy and our future opportunities to accelerate innovation, growth, and performance overall.
  • Now I'd like to turn it over to Heather and Joel, who will share details on individual segment results, financial performance, and updated guidance.
  • Sales in our Medical Products & Therapies, or MPT segment, were $1.3 billion and increased 1% in the quarter.
  • Performance in the quarter reflected strong demand for Advanced Surgery products, offset by softness in infusion therapies and technologies, or ITT.
  • We continue to believe that hospitals will return to historic practices over time.
  • The Baxter program provides participating healthcare organizations with dedicated on-demand inventory warehoused here in the U.S.
  • Sales in Advanced Surgery products totaled $296 million and grew 5% globally.
Read the full Q2 2025 transcript
SourcesCompany financials · earnings call Last updated

See how VectorShift works for your firm

Request Demo